



## **Ending the HIV-AIDS Pandemic - Follow the Science**

http://www.nejm.org/doi/full/10.1056/NEJMp1502020

- ✓ Early promise of durable effects from combination therapy has been realized for many patients: between 2000 and 2014, the rollout of ART saved an estimated 7.8 million lives worldwide
- ✓ The timing of ART initiation has remained the subject of intense debate, but today, a series of
  efficacy studies conducted over a period of more than a decade has fundamentally changed
  this discussion
- ✓ Promising data on the concept of using ART for HIV prevention in HIV-negative persons preexposure prophylaxis (PrEP), and IPERGAY study findings demonstrate safety and efficacy of "on-demand" PrEP
- ✓ Benefits of prompt initiation of ART, regardless of the CD4+ T-cell count, outweigh the risks
- ✓ Three critical questions asked and answered: risks of toxic effects of long-term ART, can viral suppression prevent forward transmission, does initiating treatment at normal or near-normal CD4+ T-cell counts actually benefit the person being treated
- ✓ As a triad of critical clinical trials, SMART, HPTN 052, and START settle the debate concerning early initiation of ART
- ✓ These studies provide an evidence-based blueprint for effective treatment and prevention of HIV infection, now political will must provide financial and human resources necessary to dramatically scale up HIV testing and treatment around the world

http://medicalenglish.univ-nantes.fr